Transforming drug discovery through
AI, genomics and iPSCs
Greenstone Biosciences stands at the forefront of biotechnological innovation, combining the power of Artificial Intelligence (AI) and human induced Pluripotent Stem Cells (hiPSC) to revolutionize the drug discovery process. Our mission is to accelerate the development of effective therapies for patients by harnessing our cutting-edge AI-hiPSC platform. This unique integration facilitates a more efficient, precise, and transformative approach to identifying potential therapeutic compounds, ultimately expediting the journey from laboratory research to patient care.
Transforming drug discovery through
AI and hiPSCs
Greenstone Biosciences stands at the forefront of biotechnological innovation, combining the power of Artificial Intelligence (AI) and human induced Pluripotent Stem Cells (hiPSC) to revolutionize the drug discovery process. Our mission is to accelerate the development of effective therapies for patients by harnessing our cutting-edge AI-hiPSC platform. This unique integration facilitates a more efficient, precise, and transformative approach to identifying potential therapeutic compounds, ultimately expediting the journey from laboratory research to patient care.
Sign up now & stay ahead of the curve! News publications and news about drug discovery are waiting for you!
Fill out the form below!
We Are Greenstone
Our mission is transforming drug discovery and accelerating the development of effective therapies for patients.
The Largest hiPSC Biobank
Greenstone, situated at Stanford Research Park within the Alexandria Center for Life Sciences, is a multifaceted platform advancing drug discovery. Beyond computational biology, we house a comprehensive iPSC biobank, accelerating the development of effective therapies for patients.
discover our innovative technology
Be a part of an ambitious team with limitless potential
Do you want to be a part of an innovative company that helps patients? If you share our vision, contact us.
follow our latest news
Greenstone scientists and collaborators regularly publish in peer-reviewed publications to inform the scientific community of discoveries from Greenstone labs and our collaborators.
Greenstone Biosciences is a proud sponsor of the 2024 Stanford Drug Discovery Symposium that was held at Stanford between April 29-30.
Congratulations to Greenstone for co-publishing in Nature Biomedical Engineering
Tachycardia-induced metabolic rewiring as a driver of contractile dysfunction.
Tu C, Caudal A, Liu Y, Gorgodze N, Zhang H, Lam CK, Dai Y, Zhang A, Wnorowski A, Wu MA, Yang H, Abilez OJ, Lyu X, Narayan SM, Mestroni L, Taylor MRG, Recchia FA, Wu JC. Nat Biomed Eng. 2023 Nov 27.